Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine for Maintaining Remission in Ulcerative Colitis
NCT02962245Phase 4Withdrawn
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Nov 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of berberine in ulcerative colitis (UC) (2 arms), sponsored by Xijing Hospital of Digestive Diseases. Primary endpoint: Annual Recurrence Rate at 1 year. Planned start Nov 2016; status: withdrawn.
02
Drugs
berberine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02962245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02962245.